Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Technology appraisal guidance
Reference number: TA584
Published:
The company who produces atezolizumab, Roche, have provided an update on regulatory timings. As a consequence, this appraisal has been rescheduled to better align with these and the first committee meeting has been scheduled for 17 January 2019.